JIANGSU HENGRUI PHARMACEUT-A

Overview

Jiangsu Hengrui Pharmaceuticals is a China-based pharmaceutical company engaged in drug research and development, manufacturing, and commercialization. Its portfolio spans innovative medicines and generics, with key therapeutic areas including oncology, metabolic and cardiovascular diseases, autoimmune conditions, and central nervous system disorders. The company states its mission as “Promote a healthier life for humankind through advancements in science.” [1]+3

China is Hengrui’s established commercial base, while licensing, partnerships, and international clinical development support its global expansion. In 2025, the company reported revenue of RMB31.63 billion, approximately 9,000 commercial full-time-equivalent staff, and 12 manufacturing facilities; the commercial staffing figure is not a total employee count.[5][6] [1]+5

Products & services

Jiangsu Hengrui’s products include medicines across oncology, metabolic and cardiovascular disease, immunology, and other therapeutic areas. Oncology examples include camrelizumab (PD-1), dalpiciclib (CDK4/6), rezvilutamide (androgen receptor), and trastuzumab rezetecan, a HER2 antibody-drug conjugate (ADC). Its disclosed portfolio also includes SHR-A2102, a Nectin-4 ADC; hetrombopag, a thrombopoietin-receptor agonist; and candidates across ADCs, antibodies, fusion proteins, small molecules and radionuclide drug conjugates.[7]

Other named products include henagliflozin (SGLT-2) and retagliptin (DPP-4) for type 2 diabetes; recaticimab (PCSK9) for lipid disorders; vunakizumab (IL-17A) for inflammatory conditions; ivarmacitinib (JAK1); and remimazolam for sedation and general anesthesia. The company reported 24 marketed innovative medicines at year-end 2025, including seven newly approved that year. In 2025, innovative-drug sales were RMB16.342 billion, or 58.3% of drug sales; oncology contributed RMB13.240 billion and non-oncology RMB3.102 billion. In 2026Q1, innovative-drug sales were RMB4.526 billion, representing 61.69% of drug sales.[8]+2

Manufacturing capabilities cover small-molecule drugs, monoclonal antibodies, ADCs, peptides, siRNA, mRNA and radioligand drug products. Disclosed commercial services include licensing arrangements that can involve intellectual-property licenses, R&D services and license options; licensing revenue was RMB1.991 billion in the first half of 2025.[11]+2 [7]+6

Geographic presence

Hengrui’s registered office and principal base are in Lianyungang, Jiangsu, where it also lists a branch office. Its FY2025 report identifies operating subsidiaries with research, manufacturing and sales activities in Shanghai, Suzhou and Chengdu.[14]+2 The company’s official production-system information lists bases in Lianyungang, Chengdu, Xiamen, Guangzhou, Tianjin, Jinan, Suzhou and Shanghai.[17]

Its domestic sales network covered more than 25,000 hospitals and 200,000 offline pharmacies across more than 30 provincial-level regions in China in FY2025.[18] Overseas markets named in the FY2025 report include the United States and Europe; the company’s international page says products are commercialized in more than 50 countries.[19][20]

The company reports 15 R&D centers across Asia, Europe, the United States and Australia, including an Innovation R&D Center in Shanghai.[4][21] The FY2025 report does not provide a country- or region-level revenue breakdown.[22] [14]+13

Business segments

Jiangsu Hengrui Pharmaceuticals reports one operating segment: research and development, manufacture and sale of pharmaceutical products. This segment accounted for 100% of FY2025 consolidated revenue, RMB31,629.416 million; the company does not disclose a separate revenue breakdown within it.[22][5]

Oncology and cardiovascular/metabolic are discussed as therapeutic-area groupings, rather than separately reported accounting segments. The cited report does not provide revenue contributions for these areas.[23]+2 [22]+4

Company history

Jiangsu Hengrui Pharmaceutical traces its origins to Lianyungang Pharmaceutical Factory, established in 1970. The company was established as a joint-stock company in April 1997 and listed on the Shanghai Stock Exchange in October 2000.[26][14] In 2011, imrecoxib became its first approved innovative drug.[26]

Hengrui expanded its oncology portfolio with the 2014 approval of apatinib, followed by the launches of pyrotinib in 2018 and camrelizumab in 2019.[27] In January 2023, camrelizumab in combination with apatinib was approved in China as a first-line treatment for unresectable or metastatic hepatocellular carcinoma.[28] The company’s shares began trading on the Hong Kong Stock Exchange in May 2025, alongside its Shanghai listing.[29] [14]+4

Sources

• JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y)
  16 citations

  [1][5][7][9][12][14][15][16][18][19][22][23][24][25][27][29]
• JIANGSU HENGRUI PHARMACEUT-A — Presentation (2025 Y)
  5 citations

  [2][3][6][8][11]
• www.hengrui.com[4]
• JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2026 Q 1)[10]
• JIANGSU HENGRUI PHARMACEUT-A — Presentation (2025 H 1)[13]
• www.hengrui.com[17]
• www.hengrui.com[20]
• www.hengrui.com[21]
• www.hengrui.com[26]
• www.hengrui.com[28]